Development of Liposomal Dry Powder Inhalation to Increase the Effectiveness of Tuberculosis Therapy

Tuberculosis (TB) is one of the most threatening infectious diseases for Indonesian people. The number of TB patients in 2020 was estimated at 845,000 people with 98,000 deaths. One of the factors that causes difficulty in TB therapy is the lack of adherence and the slow development of new antibiotics when antibiotic resistance appears. The development of nanotechnology-based preparation has the potential to increase the therapeutic effectiveness of the active ingredients, such as in the dry powder inhaler form, which allows the active ingredients to be delivered efficiently to the lungs as the target organs. Keywords: tuberculosis, liposomes, antibiotics, dry powder inhalatio